De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Inhibikase Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Inhibikase Therapeutics' is Milton Werner, benoemd in Jun2010, heeft een ambtstermijn van 13.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 744.06K, bestaande uit 67.3% salaris en 32.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 16.63% van de aandelen van het bedrijf, ter waarde € 1.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 2.8 jaar.

Belangrijke informatie

Milton Werner

Algemeen directeur

US$744.1k

Totale compensatie

Percentage CEO-salaris	67.3%
Dienstverband CEO	13.3yrs
Eigendom CEO	16.6%
Management gemiddelde ambtstermijn	8.9yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Milton Werner's beloning veranderd ten opzichte van Inhibikase Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$744k	US$501k	-US$18m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$611k	US$455k	-US$15m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$961k	US$293k	-US$3m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$3m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$385k	US$293k	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$535k	US$452k	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 744.06K ) Milton } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: De vergoeding van Milton is gestegen terwijl het bedrijf verliesgevend is.

CEO

Milton Werner (59 yo)

13.3yrs

Tenure

US$744,055

Compensatie

Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Milton Werner	CEO, President & Director	13.3yrs	US$744.06k	16.63% $ 1.2m
Joseph Frattaroli	Chief Financial Officer	5.4yrs	US$574.77k	0.012% $ 859.0
Roger Rush	Head of Preclinical Research	8.7yrs	geen gegevens	geen gegevens
Surendra Singh	Head of Chemistry	9.1yrs	geen gegevens	geen gegevens
Charles Olanow	CEO of Clintrex Research Corporation & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dan Williams	Controller	no data	geen gegevens	geen gegevens

8.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van IQT0 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Milton Werner	CEO, President & Director	13.3yrs	US$744.06k	16.63% $ 1.2m
Charles Olanow	CEO of Clintrex Research Corporation & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Grint	Independent Director	2.8yrs	US$84.62k	0% $ 0
Dennis Berman	Independent Director	2.8yrs	US$78.62k	0% $ 0
Kenneth Marek	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Kordower	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roy Freeman	Independent Director	2.8yrs	US$69.62k	0% $ 0
Robert Hauser	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Karl Kieburtz	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gisele Dion	Independent Director	less than a year	US$58.89k	geen gegevens
Ted Dawson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Valina Dawson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IQT0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Inhibikase Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd